Two Giants Dominate IHE, Making It Riskier Than It Looks
As of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
This guide weighs the advantages and drawbacks of target date versus lifecycle funds to help you pick the option that best fits your retirement plan.
25,428 articlesAs of March 2026, the iShares U.S. Pharmaceuticals ETF is heavily keyed to two drugmakers, exposing investors to outs...
Fidelity’s Active Large Growth ETF threads a narrow but meaningful edge over passive peers as AI-enabled demand fuels...
Bloom Energy surged to the forefront in 2026 with double-digit gains and a massive market cap, while FuelCell Energy ...
A hypothetical turn of events on a 66th birthday offers a powerful lens on money management. Learn how to shield your...
As the broad market declines, three oil and gas ETFs stay in the green, illustrating how energy exposure can act as a...
Small-cap value has accelerated ahead of growth in 2026, with three ETFs leading the pack by delivering a clear facto...
A real-world financial wake-up call shows how a missing tarantula collection can expose gaps in protection, insurance...
Retail traders flock to energy names, lifting broad ETFs even as oil prices warn of a choppier path. This report trac...
A low-cost Emerging Markets ETF is quietly outperforming many active EM funds in 2026, raising questions about fees, ...
Through March 21, 2026, VT is down less than 1% year-to-date while SPY slides about 3%, signaling a shift toward glob...
A new survey of 351 institutions finds 25% intend to add XRP in 2026, joining the 18% already holding the token. Pric...
A CFO selling a substantial stake can spark questions about a company’s short-term risk and long-term strategy. This ...